ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
+12.77%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$616M
AUM Growth
+$616M
(+19%)
Cap. Flow
+$33.1M
Cap. Flow
% of AUM
5.37%
Top 10 Holdings %
Top 10 Hldgs %
49.49%
Holding
239
New
40
Increased
61
Reduced
56
Closed
33
Top Buys
| 1 |
Keros Therapeutics
KROS
|
$52.1M |
| 2 |
Prothena Corp
PRTA
|
$20.5M |
| 3 |
SPDR S&P 500 ETF Trust
SPY
|
$14M |
| 4 |
CytomX Therapeutics
CTMX
|
$6.89M |
| 5 |
ABVX
Abivax
ABVX
|
$6.59M |
Top Sells
| 1 |
RAPT Therapeutics
RAPT
|
$41.5M |
| 2 |
Roivant Sciences
ROIV
|
$17.4M |
| 3 |
SWTX
SpringWorks Therapeutics
SWTX
|
$8.63M |
| 4 |
Immunovant
IMVT
|
$6.94M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$6.34M |
Sector Composition
| 1 | Healthcare | 83.61% |
| 2 | Financials | 2.95% |
| 3 | Consumer Discretionary | 0% |
| 4 | Utilities | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
RAPT Therapeutics
RAPT
$188M
| $6.27M | 0.96% |
783,217
-5,187,551
| -87% | -$41.5M |
|
|
AAM
27
AA Mission Acquisition Corp.
AAM
$462M
| $6.03M | 0.92% |
578,359
| – | – |
|
28
Ionis Pharmaceuticals
IONS
$6.8B
| $5.87M | 0.9% |
+148,461
| New | +$5.87M |
|
29
Teva Pharmaceuticals
TEVA
$21.1B
| $5.8M | 0.89% |
345,878
-177,889
| -34% | -$2.98M |
|
|
OACCU
30
Oaktree Acquisition Corp. III Life Sciences Unit
OACCU
| $5.48M | 0.84% |
516,482
| – | – |
|
|
VERV
31
DELISTED
Verve Therapeutics
VERV
| $5.27M | 0.81% |
+469,018
| New | +$5.27M |
|
32
Revolution Medicines
RVMD
$7.1B
| $4.93M | 0.76% |
134,136
-43,000
| -24% | -$1.58M |
|
|
BBOT
33
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $4.7M | 0.72% |
442,615
-27,114
| -6% | -$288K |
|
34
iShares 1-3 Year Treasury Bond ETF
SHY
$24.5B
| $4.42M | 0.68% |
53,337
-50,000
| -48% | -$4.14M |
|
35
Rezolute
RZLT
$619M
| $4.41M | 0.68% |
989,297
-126,750
| -11% | -$565K |
|
36
Mineralys Therapeutics
MLYS
$1.03B
| $4.09M | 0.63% |
302,125
+38,700
| +15% | +$524K |
|
|
CNTA
37
Centessa Pharmaceuticals
CNTA
$2.25B
| $3.9M | 0.6% |
296,766
+80,600
| +37% | +$1.06M |
|
38
Monopar Therapeutics
MNPR
$211M
| $3.61M | 0.55% |
100,974
+200
| +0.2% | +$7.16K |
|
39
Sarepta Therapeutics
SRPT
$1.78B
| $3.6M | 0.55% |
210,313
+87,392
| +71% | +$1.49M |
|
40
Ardelyx
ARDX
$1.53B
| $3.59M | 0.55% |
915,130
+424,387
| +86% | +$1.66M |
|
|
THRD
41
DELISTED
Third Harmonic Bio
THRD
| $3.38M | 0.52% |
622,873
+522,873
| +523% | +$2.84M |
|
42
Vaxcyte
PCVX
$4B
| $3.19M | 0.49% |
98,032
+85,232
| +666% | +$2.77M |
|
43
Rhythm Pharmaceuticals
RYTM
$6.85B
| $2.87M | 0.44% |
45,390
+8,500
| +23% | +$537K |
|
|
VRNA
44
Verona Pharma
VRNA
$9.16B
| $2.69M | 0.41% |
28,450
+8,450
| +42% | +$799K |
|
45
Alector
ALEC
$238M
| $2.41M | 0.37% |
1,723,526
+1,343,196
| +353% | +$1.88M |
|
46
Viridian Therapeutics
VRDN
$1.5B
| $2.38M | 0.37% |
170,598
+91,598
| +116% | +$1.28M |
|
|
ASPC
47
A SPAC III Acquisition Corp. Class A Ordinary Shares
ASPC
$83M
| $2.2M | 0.34% |
215,000
| – | – |
|
48
CorMedix
CRMD
$1.11B
| $2.16M | 0.33% |
+175,000
| New | +$2.16M |
|
49
NewAmsterdam Pharma
NAMS
$2.71B
| $2.03M | 0.31% |
+112,359
| New | +$2.03M |
|
50
Delcath Systems
DCTH
$385M
| $2.03M | 0.31% |
149,385
| – | – |
|